Licensing · MENA · Announced 28 Sept 2026
Dr. Reddy's Laboratories → Hikma Pharmaceuticals
Hikma gets multi-year exclusive MENA rights to Nicotinell. Dr. Reddy's stays brand owner and supplier, and Hikma brings registration and regional reach.
Parties: Dr. Reddy's Laboratories SA (Switzerland) → Hikma Pharmaceuticals International Ltd (Switzerland)
- Deal type
- Licensing
- Value
- Not stated
- Territory
- MENA
- Therapeutic area
- Consumer health
- Asset
- Nicotinell® — nicotine replacement therapy (patch, gum, lozenge)
- Announced
- 28 Sept 2026
Our analysis
A multi-year exclusive licence giving Hikma the right to register, market and distribute Nicotinell across MENA — an OTC, consumer-health smoking-cessation brand, not a prescription medicine.
Dr. Reddy's stays brand owner and supplier; Hikma supplies regional registration and commercial reach. The deal is executed Swiss entity to Swiss branch (DRL SA ↔ Hikma International's Swiss branch) — a standard IP/tax-efficient structure for global brand licences, recorded here for accuracy.
The full analysis is free to read with a work email on this page.
Source: ZAWYA